Skip to content
DataLookout
Menu

VIBRANTNCT07920367

Non-Invasive Biomarker Monitoring in UC on Biologics

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Faecal VOC discrimination of therapeutic versus sub-therapeutic biologic trough concentration
Timeframe: From enrollment to the end of treatment at 8 weeks

Secondary (6)

Urinary VOC discrimination of therapeutic versus sub-therapeutic trough concentration (cross-validated AUROC, 95% CI)
Change in cross-validated AUROC when VOC features are added to models containing FCP, CRP and cytokines
Association between faecal VOC features and microbiota composition and diversity (FDR-adjusted)
Association between faecal VOC features and blood DNA methylation, including interaction with remission/relapse status (FDR-adjusted
Faecal VOC discrimination of remission versus relapse (cross-validated AUROC, 95% CI)
Show 1 moreShow less
Difference in cross-validated AUROC between faecal and urinary VOC models (paired DeLong test)

Arms and interventions

Infliximab

Adults with UC on maintenance IV infliximab. Standard-care maintenance intravenous therapy; not assigned or altered by the study.

Vedolizumab

Adults with UC on maintenance IV vedolizumab. Standard-care maintenance intravenous therapy; not assigned or altered by the study.

Sites

1 site in 1 country

  • University Hospitals Coventry and Warwickshire NHS TrustCoventry, United Kingdom